Voyager Therapeutics (NASDAQ:VYGR) vs. Inhibrx Biosciences (NASDAQ:INBX) Head-To-Head Survey

Voyager Therapeutics (NASDAQ:VYGR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Institutional & Insider Ownership

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Voyager Therapeutics and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-416.32%	-59.83%	-46.85%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Valuation & Earnings

This table compares Voyager Therapeutics and Inhibrx Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$34.46 million	3.33	-$119.72 million	($1.73)	-1.08
Inhibrx Biosciences	$1.30 million	957.03	-$140.05 million	($8.88)	-9.52

Voyager Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Voyager Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 4.03, indicating that its share price is 303% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Voyager Therapeutics and Inhibrx Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1	0	2	1	2.75
Inhibrx Biosciences	1	2	2	1	2.50

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 784.72%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 133.67%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Inhibrx Biosciences.

Summary

Voyager Therapeutics beats Inhibrx Biosciences on 8 of the 13 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.